All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Survival outcomes in patients with MF undergoing transplantation: Role of comorbidities and BMI

Apr 1, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

Bookmark this article

For patients with myelofibrosis (MF), transplant suitability is determined by several factors, including age, disease status, comorbidities, performance status, and donor availability, and is currently, based on the Myelofibrosis Transplant Scoring System (MTSS).1

Recently, a new scoring system, the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI), has been identified to assess role of comorbidities and body mass index (BMI) in transplant prognostication for patients with MF. Here, we summarize a retrospective study by Polverelli N et al.1

Study design1

  • Patients with MF who had not undergone transplant but were selected to undergo transplant in chronic phase were included in this study.
  • Endpoints included overall survival (OS) and non-relapse mortality (NRM) in patients classed as low-, intermediate-, or high-risk according to the HCT-CI.

Key findings1

  • Overall, 4,086 patients with MF were included in the analysis, and 54% of patients with comorbidity data had 1 comorbidity.
    • Pulmonary conditions were most prevalent (12.7% were moderate, and 6.8% were severe).
    • Prevalence of massive splenomegaly was lower in high-risk vs intermediate- and low-risk patients (17% vs 22% and 28%, respectively).
  • The 5-year NRM and OS rates were higher in patients assessed as high-risk compared with low-risk, according to the HCT-CI (Table 1).
    • This indicated that comorbidities continue to impact transplant outcomes and should be part of the transplant selection process alongside existing criteria.

Table 1. 5-year survival rates in patients with low-, intermediate-, and high-risk patients with MF*

Category, % (unless stated otherwise)

Low risk (0),
n = 1,701

Intermediate risk (1,2),
n = 762

High risk (3),
n = 694

5-year NRM




5-year OS




OS, overall survival; NRM, non-relapse mortality.
*Adapted from Polverelli N, et al.1

  • No significant differences were found across BMI groups and NRM, and OS (p = 0.5 and p = 0.3, respectively).
    • In this context, patients who are overweight and obese should not be excluded from transplant. However, this contrasts with findings from other studies, and further evaluation is needed to clarify the role of BMI in transplant outcomes.

Key learnings 

  • HCT-CT is a prognostically significant assessment for patients with MF undergoing transplant and may increase understanding of risk factors and guiding decision-making in transplant considerations.
  • BMI has little impact on transplant outcomes in this population, whilst comorbidities do impact outcomes.
  • Future studies aiming to validate these findings and assessments could further enhance the evaluation for patients with MF undergoing transplant consideration, especially the integration of comorbidity assessments alongside existing scoring systems.

  1. Polverelli N, Bonneville E, de Wreede L, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. Online ahead of print. DOI: 10.1002/ajh.27262


Subscribe to get the best content related to MPN delivered to your inbox